Drug Trial Radar · NCT07766473
First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Mar 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Filamon LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD). Approximately 24 participants with stable wet AMD who have previously received at least three anti- Vascular Endothelial Growth Factor (anti -VEGF) injections will use the eye gel for up to 12 weeks at one of three dosing schedules (once, twice, or three times daily). Standard anti-VEGF treatment (aflibercept) will remain available if needed during the study. Participants who complete the initial 12-week treatment period may be invited to continue in an extension phase for up to 12 months to collect additional safety and treatment information.
Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
Interventions
BETA-TT8 ophthalmic gel 3.8% w/vDrug
A selective small-molecule inhibitor of the MEK/ERK (MAPK) signalling pathway, topical ophthalmic gel.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety of topical BETA-TT8 based on TEAEs.Time frame: 12 weeks
- To evaluate the safety of topical BETA-TT8 based on DLTs.Time frame: 12 weeks
- To evaluate the safety of topical BETA-TT8 based on clinically significant ocular findings.Time frame: 12 weeks
- To evaluate the safety of topical BETA-TT8 based on intraocular pressure changes.Time frame: 12 weeks
- To evaluate the safety of topical BETA-TT8 based on corneal staining abnormalities.Time frame: 12 weeks
- To evaluate the tolerability of topical BETA-TT8 based on reasons for discontinuations.Time frame: 12 weeks
- To evaluate the safety of topical BETA-TT8 based on TEAEs.Time frame: 12 weeks
- To evaluate the safety of topical BETA-TT8 based on TEAEs.Time frame: 12 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Central Coast Eye Specialist
Gosford, New South Wales, Australia
Sydney Eye Hospital
Sydney, New South Wales, Australia
Sydney West Retina
Westmead, New South Wales, Australia
Cerulea Clinical Trials
East Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.